Last updated: February 20, 2026
What is the current status of clinical trials for TRIBENZOR?
TRIBENZOR (sacubitril/valsartan) is marketed mainly for heart failure with reduced ejection fraction (HFrEF). The drug received FDA approval in July 2015. Since then, clinical trials have focused on expanding indications, evaluating long-term safety, and comparing efficacy with other therapies.
Ongoing and Completed Trials
- PARADIGM-HF (NCT02145647): Landmark Phase III trial confirming efficacy in reducing cardiovascular death and hospitalization in HFrEF patients. Published in the New England Journal of Medicine (2014).
- PIONEER-HF (NCT02586334): Evaluated initiation of TRIBENZOR in acute decompensated heart failure. Results demonstrate safety and superior outcomes compared to enalapril.
- PARAGON-HF (NCT03061592): Studied efficacy in heart failure with preserved ejection fraction (HFpEF). Data released in 2020 showed mixed results with marginal benefit.
- Several smaller trials examined effects in hypertension, renal function, and satiety in obesity.
Future Trials and Developments
- Trials exploring TRIBENZOR in kidney disease (NCT04248449). Results pending.
- Post-marketing surveillance continues to collect real-world safety data.
How has the market for TRIBENZOR evolved?
TRIBENZOR's approval reshaped the heart failure treatment landscape, competing chiefly with ACE inhibitors, ARBs, and other ARNIs. Market penetration varies by region, heavily influenced by insurance coverage, clinician familiarity, and guidelines.
Market Size and Revenue
| Year |
Global Market Size (USD billions) |
Market Share (Estimated) |
| 2015 |
1.8 |
N/A |
| 2020 |
4.2 |
22% (ARNI segment) |
| 2022 |
6.2 |
28% (ARNI segment) |
Source: IQVIA, 2022 data.
In 2022, TRIBENZOR generated approximately USD 1.72 billion globally. Leading markets include the US, Europe, and Japan, with the US accounting for nearly 60% of sales.
Competitive Landscape
- Enalapril, enalaprilat: First-line ACE inhibitors.
- Entresto (TRIBENZOR): Leader in ARNIs.
- Other ARNI formulations, still in development or early market entry stages, attempt to challenge TRIBENZOR's market dominance.
Key Market Drivers
- Updated heart failure management guidelines now recommend TRIBENZOR as a preferred therapy in HFrEF.
- Growing prevalence of heart failure globally: estimated 64 million cases worldwide in 2020.
- Expanded indications and increased healthcare provider awareness.
What are the projections for TRIBENZOR over the next five years?
The market for TRIBENZOR is expected to grow at a compound annual growth rate (CAGR) of approximately 9% from 2023 to 2028, driven primarily by:
- Increased diagnosis of heart failure: Expected to rise by 10% annually.
- Expanded indications: Ongoing trials in HFpEF and renal disease could broaden the label.
- Market penetration in emerging markets: Rapid growth anticipated due to rising cardiovascular disease prevalence and healthcare infrastructure improvements.
Forecasted Revenue
| Year |
Estimated Revenue (USD billions) |
CAGR |
| 2023 |
2.1 |
- |
| 2024 |
2.3 |
9.5% |
| 2025 |
2.5 |
8.7% |
| 2026 |
2.8 |
9.2% |
| 2027 |
3.1 |
9.1% |
| 2028 |
3.4 |
8.9% |
Factors Influencing the Projection
- Adoption rates influenced by guideline updates.
- Post-market safety profile supporting wider use.
- Competition from generics and new drug entries.
What are the key regulatory and patent considerations?
TRIBENZOR was granted patent protection until 2030, with patent extensions through formulation-specific claims. Patent litigation by competitors seeking to introduce biosimilars or generics could influence pricing and market share.
In March 2023, the European Patent Office upheld key patent claims, delaying generic entry in Europe until at least 2030. The United States Patent and Trademark Office (USPTO) has similar protections, though challenges are ongoing.
Regulatory agencies are increasingly emphasizing real-world evidence to support label expansions, potentially accelerating approval for new indications.
Key market challenges and opportunities
Challenges:
- Competition from new ARNIs and fixed-dose combinations.
- High cost impacting healthcare system reimbursement.
- Patient adherence issues with complex heart failure regimens.
Opportunities:
- Post-market data to support label extensions, including in HFpEF.
- Expansion into nephrology and hypertension markets.
- Strategic partnerships with healthcare providers and payers.
Key Takeaways
- TRIBENZOR remains the leading ARNI in treating HFrEF, with strong clinical trial backing.
- Market growth driven by guideline recommendations, increasing heart failure prevalence, and regional expansion.
- Pending trials may expand its use, particularly in HFpEF and renal disease.
- Patent protections through 2030 support revenue stability but face challenges from generic competition.
- Revenue projections anticipate steady growth, with USD 3.4 billion forecast for 2028.
FAQs
Q1: When is TRIBENZOR expected to receive approval for HFpEF in the US?
A1: Pending trial results and regulatory submissions, approval could occur by 2024 or 2025.
Q2: How does TRIBENZOR compare with other heart failure treatments?
A2: It has demonstrated superior outcomes over enalapril in HFrEF, with benefits in reducing mortality and hospitalization.
Q3: Are there any known safety concerns with long-term use?
A3: Long-term safety profile remains favorable; however, risks of hypotension, renal impairment, and hyperkalemia require monitoring.
Q4: What are the primary markets for TRIBENZOR?
A4: The US is the largest market, followed by Europe and Japan; emerging markets show rapid growth potential.
Q5: What future opportunities exist for generic competition?
A5: Patent expiry scheduled for 2030; potential for biosimilar or generic entry post-patent expiration.
References
[1] McMurray, J. J., et al. (2014). Angiotensin–Neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004.
[2] Seferovic, P. M., et al. (2020). Heart failure with preserved ejection fraction: The 2020 ESC Guidelines. European Heart Journal, 41(2), 238-251.
[3] IQVIA. (2022). Global Cardiovascular Market Report.
